Table 2.
Active | Placebo | |||||
---|---|---|---|---|---|---|
Baseline | Month 3 | Month 6 | Baseline | Month 3 | Month 6 | |
WC (cm) | 101.1 ± 9.9 | 98.5 ± 10.5 # | 97.2 ± 10.7 *# | 103.4 ± 11.0 | 101.3 ± 11.4 # | 101.7 ± 11.7 # |
HC (cm) | 113.4 ± 6.9 | 111.0 ± 7.5 # | 110.1 ± 7.5 *# | 115.6 ± 7.2 | 113.6 ± 6.7 # | 113.5 ± 7.2 # |
Weight (kg) | 88.4 ± 11.2 | 85.5 ± 11.5 # | 84.7 ± 11.7 *# | 90.8 ± 13.8 | 89.0 ± 14.1 # | 88.8 ± 14.5 # |
Weight loss (%) | −3.2 ± 3.7 # | −4.2 ± 5.0 *# | −2.1 ± 3.3 | −2.2 ± 4.2 # | ||
BMI (kg/m2) | 29.5 ± 1.6 | 28.6 ± 2.0 # | 28.3 ± 2.2 *# | 29.4 ± 1.4 | 28.9 ± 1.7 # | 28.8 ± 1.9 # |
Lean Mass (kg) | 54.0 ± 11.3 | 52.5 ± 10.1 | 52.4 ± 10.2 # | 56.1 ± 13.0 | 55.4 ± 12.8 | 55.6 ± 13.2 # |
FM (kg) | 32.1 ± 7.2 | 30.6 ± 6.4 *# | 29.7 ± 6.7 *# | 33.1 ± 7.5 | 31.8 ± 8.0 # | 31.2 ± 8.2 # |
FM Arm (kg) | 3.9 ± 1.1 | 3.7 ± 0.9 | 3.6 ± 0.9 # | 3.7 ± 1.0 | 3.6 ± 1.0 | 3.5 ± 1.0 # |
FM Leg (kg) | 11.9 ± 3.3 | 11.4 ± 3.2 | 11.4 ± 3.8 # | 12.2 ± 3.8 | 11.5 ± 4.0 | 11.3 ± 3.6 # |
FM abdominal (trunk) (kg) | 15.9 ± 3.3 | 14.6 ± 3.5 *# | 14.1 ± 3.5 *# | 16.3 ± 4.1 | 15.6 ± 4.4 # | 15.3 ± 4.4 # |
Android Fat (kg) | 3.6 ± 1.8 | 2.7 ± 1.0 # | 2.6 ± 1.0 # | 4.0 ± 2.1 | 3.1 ± 1.4 | 3.0 ± 1.4 # |
Gynoid Fat (kg) | 7.0 ± 3.8 | 5.2 ± 1.5 # | 5.1 ± 1.5 # | 7.7 ± 4.0 | 5.9 ± 2.8 # | 5.9 ± 2.8 # |
Visceral Fat (g) | 632.9 ± 223.5 | 588.6 ± 245.3 # | 554.2 ± 232.4 *# | 632.8 ± 249.6 | 581.5 ± 256.6 # | 575.8 ± 254.9 # |
Visceral Fat Area (cm2) | 131.4 ± 46.4 | 122.0 ± 51.0 | 115.6 ± 47.4 # | 131.5 ± 52.0 | 120.1 ± 53.1 | 118.6 ± 52.6 # |
Subcutaneous Fat (kg) | 15.2 ± 3.1 | 14.0 ± 3.4 # | 13.5 ± 3.4 *# | 15.7 ± 3.9 | 15.0 ± 4.2 # | 14.7 ± 4.3 # |
# Indicated significant decrease from baseline within group (p < 0.05); * indicates significant difference between groups (p < 0.05) in ITT analysis; (DEXA measures baseline placebo n = 69, active n = 62; 3- and 6-month placebo n = 56, active n = 46). WC = waist circumference; HC = hip circumference; BMI = body mass index; FM = fat mass.